Iambic Therapeutics, Inc.
NNASDAQ:IAM14.67
USD
-1.13
(-7.15%)
CIK
1997038
ISIN
US45076A1016
CUSIP
45076A101
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Thomas Miller
- Full Time Employees
- 171
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 5627 Oberlin Drive, Suite 120 San Diego CA United States 92121
- IPO Date
- Oct 15, 2026
- CIK
- 0001997038
- Website
- iambic.ai
- Similar Companies
- Business
- Iambic Therapeutics, Inc. develops AI driven platform for drug discovery. It combines proprietary AI-driven platforms with the expertise of experienced drug discovery scientists to identify, design, and optimize novel therapeutic candidates across a range of disease areas. The company was founded by Thomas Miller and Fred Manby on October 14, 2019 and is headquartered in San Diego, CA.
Company News
U.S. IPO Weekly Recap: Biotechs City Therapeutics And Iambic Headline The Week's Pricings
Iambic Announces Pricing of Initial Public Offering
Nvidia-backed Iambic Therapeutics targets up to $806 million valuation in US IPO
Docusign Declines 7.2% Since Beating Q1 Earnings & Revenue Estimates
New Bitdefender Survey of 1,200 Cybersecurity Professionals Reveals Top Concerns and Challenges for Businesses Globally
Entrust Completes Acquisition of Onfido, Creating A New Era of Identity-Centric Security